BCG: Past, Present and Future. Nwora Lance Okeke, MD, MPH August 24, 2016
|
|
- Evangeline Carson
- 5 years ago
- Views:
Transcription
1 BCG: Past, Present and Future Nwora Lance Okeke, MD, MPH August 24, 2016
2 Disclosures Nothing to disclose
3 Overview Introduction and History Current Use Effectiveness Non-vaccine uses of BCG
4 Edmond Nocard ( ) Albert Calmette ( ) Camille Guerin ( ) Courtesy of Wellcome Library, London, the Pasteur Institute, Phototheque Biu Sante Paris
5 Early Timeline 1882: Koch identifies M. tuberculosis as cause of human disease 1900: Calmette and Guerin discover that tubercle bacilli can be attenuated using ox bile 1902: Virulent strain of mycobacterium isolated from cows with mastitis by Nocard 1908: Strain obtained by Nocard cultured up by Calmette and Guerin for the next 11 years 1913: first trials on cattle interrupted by WWI 1919: successfully inoculated attenuated bacilli in guinea pigs, rabbits, horses and cattle without progressive disease 1921: first trial in humans
6 First Human Trials : 115,000 infants administered oral BCG with zero vaccineassociated complications Sample of 8,076 children vaccinated, mortality 4.6% Unvaccinated children living under the same conditions was 16-25% Romania: 50% decreased mortality among vaccinated children (n = 80,000) Sweden: 2.3% mortality in vaccinated, 9.5% among unvaccinated (n = 4,009) New York (1930): TB associated mortality 0.8% among vaccinated children (n = 208) 8% among vaccinated children (n = 350) Proc R Soc Med 1931 (11):
7 UNESCO, 2013
8 Timeline Early 1930s: switch to intradermal administration Late 1940s: Increase in TB cases associated with WWII; WHO adopts BCG for widespread administration among at-risk individuals 1950: Large Public Health Trials Culture heterogeneity? Environmental Mycobacteria?
9 Chengalpattu Trial Trial organized by Indian Ministry of Health and US Public Health Service, WHO At 7.5 years of follow up, no protective efficacy provided by either of the vaccine strains World Health Organ Tech Rep Ser. 1980;651:1-21.
10 What is bacille Calmette-Guerin? Mycobacterium bovis Member of the mycobacterium tuberculosis family Cause of approximately 1.5% of pulmonary TB outside Africa Higher incidence of extrapulmonary manifestations due to oral ingestion as primary mode of inoculation PZA monoresistance Clinically indistinguishable from Mtb disease
11 Bacille de Calmette et Guerin M.bovis attenuated with ox bile Subcultured 230 times over 13 years Loss of virulence to all animals tested First mass-produced by the Pasteur Institute in 1931 Other major producers: Glaxo/Danish strain Tokyo Montreal OncoTICE
12 Immunogenicity of BCG No surrogate marker to quantify immune response to BCG Vaccine-induced T-cell proliferation, IFN-gamma, TNF or IL-2 release have not been directly correlated with protection against TB No demonstrable difference in immunogenicity between strains Clin Infect Dis. 2014;58(4):470.
13 Administration of BCG 0.1mg/mL x 1 dose with 27 gauge needle Intradermal or MPP Neonatal administration recommended in most high-prevalence regions Papule by 2 weeks Pustule by 6 weeks Scar by 3 months Booster dosing?
14 Who gets BCG? Neonates in countries with moderate to high-incidence of TB Annual average rate of smear positive TB > 5 per 100,000 Average rate of TB meningitis of > 1 per 100,000 in children over 5 Average annual risk of TB > 0.1%? Healthcare workers in high-incidence countries who have not been vaccinated? Persons exposed to MDR-TB World Health Organization
15 PLoS Med 8(3): e
16 BCG Worldwide One billion children in over 180 countries Given to about 100 million children worldwide every year
17 Does it work?
18 Trial Year Conducted Vaccinated/Unvaccinated Saskatchewan /303 Native American /1447 Chicago Infants /4128 Turtle and Rosebud Infants /139 Chicago Infants (TB HH) /250 Ida B. Wells Housing Project /625 US Mental Health /15 Illinois Mentally /494 Handicapped Georgia /2341 Puerto Rico Children /27338 Madanapelle /5803 Georgia/Alabama /17854 UK MRC /13300 African Gold Miners /7997 Haiti /340 Chingleput / Bombay Infants /300 Agra /1259 Clinical Infectious Diseases 2014;58(4):470 80
19 Trial Year Conducted Vaccinated/ Unvaccinated RR (95% CI) Saskatchewan / (0.06, 0.69) Native American /1447 Chicago Infants / (0.19,0.60) Turtle and Rosebud / (0.13, 1.25) Infants Chicago Infants (TB / (0.08, 1.02) HH) Ida B. Wells Housing /625 Project US Mental Health /15 Illinois Mentally /494 Handicapped Georgia /2341 Puerto Rico Children /27338 Madanapelle /5803 Georgia/Alabama /17854 UK MRC /13300 African Gold Miners /7997 Haiti /340 Chingleput / Bombay Infants / (0.35,1.07) Agra /1259
20 Trial Year Conducted Vaccinated/ Unvaccinated RR (95% CI) Saskatchewan / (0.06, 0.69) Native American /1447 Chicago Infants / (0.19,0.60) Turtle and Rosebud / (0.13, 1.25) Infants Chicago Infants (TB / (0.08, 1.02) HH) Ida B. Wells Housing /625 Project US Mental Health /15 Illinois Mentally /494 Handicapped Georgia /2341 Puerto Rico Children / (0.57,0.90) Madanapelle /5803 Georgia/Alabama /17854 UK MRC /13300 African Gold Miners /7997 Haiti /340 Chingleput / Bombay Infants / (0.35,1.07) Agra / (0.19, 0.83)
21 Trial Year Conducted Vaccinated/ Unvaccinated RR (95% CI) Saskatchewan / (0.06, 0.69) Native American /1447 Chicago Infants / (0.19,0.60) Turtle and Rosebud / (0.13, 1.25) Infants Chicago Infants (TB / (0.08, 1.02) HH) Ida B. Wells Housing /625 Project US Mental Health / (0.01,6.36) Illinois Mentally / (0.57,3.42) Handicapped Georgia /2341 Puerto Rico Children / (0.57,0.90) Madanapelle / (0.52,1.26) Georgia/Alabama / (0.56,1.53) UK MRC /13300 African Gold Miners / (0.39,1.00) Haiti / (0.01,0.91) Chingleput / (0.88, 1.25) Bombay Infants / (0.35,1.07) Agra / (0.19, 0.83)
22 Trial Year Conducted Vaccinated/ Unvaccinated RR (95% CI) Saskatchewan / (0.06, 0.69) Native American / (0.20,0.33) Chicago Infants / (0.19,0.60) Turtle and Rosebud / (0.13, 1.25) Infants Chicago Infants (TB / (0.08, 1.02) HH) Ida B. Wells Housing / (0.01, 2.87) Project US Mental Health / (0.01,6.36) Illinois Mentally / (0.57,3.42) Handicapped Georgia / (0.28, 5.58) Puerto Rico Children / (0.57,0.90) Madanapelle / (0.52,1.26) Georgia/Alabama / (0.56,1.53) UK MRC / (0.16, 0.31) African Gold Miners / (0.39,1.00) Haiti / (0.01,0.91) Chingleput / (0.88, 1.25) Bombay Infants / (0.35,1.07) Agra / (0.19, 0.83)
23 Trial Year Conducted Vaccinated/ Unvaccinated RR (95% CI) Native American / (0.20,0.33) Chicago Infants / (0.19,0.60) Puerto Rico Children / (0.57,0.90) Madanapelle / (0.52,1.26) Georgia/Alabama / (0.56,1.53) UK MRC / (0.16, 0.31) African Gold Miners / (0.39,1.00) Chingleput / (0.88, 1.25) Bombay Infants / (0.35,1.07) Agra / (0.19, 0.83)
24 Trial Criteria Metaregression RRR (95% CI) Infants (n = 5) 0.41 (0.29,0.56) School Aged Children, non-stringent TST (n = 2) 0.59 (0.35,1.01) School Aged Children, stringent TST (n = 4) 0.26 (0.18,0.37) Other Ages, non-stringent TST (n = 4) 0.81 (0.55,1.22) Other Ages, stringent TST (n = 3) 0.88 (0.59,1.31)
25 Trial Criteria Metaregression RRR (95% CI) Done at 0-20 degrees latitude 0.78 (0.58, 1.05) Done at degrees latitude 0.68 (0.48,0.95) Done at 40+ degree latitude 0.32 (0.22,0.46) Clin Infect Dis 2014;58(4):470 80
26 BCG Vaccine Efficacy Overall Risk Reduction of Pulmonary TB : 50% (Range 0-80%) Overall Risk Reduction of Meningeal and Miliary TB in Children: 85% Protective efficacy against M. leprae, M. ulcerans and invasive MAC
27 Does it work? Protection of children in high-incidence TB countries against military and meningeal TB Perhaps some protective benefit against pulmonary TB IF administered before TB (or environmental mycobacteria) exposure Strain of vaccine makes no difference
28 WHO Position BCG vaccine has a documented protective effect against meningitis and disseminated TB in children. It does not prevent primary infection and, more importantly, does not prevent reactivation of latent pulmonary infection, the principal source of bacillary spread in the community. The impact of BCG vaccination on transmission of Mtb is therefore limited...optimal utilization of BCG is encouraged World Health Organization, 2004
29 WHO Recommendations All infants as soon as possible after birth in countries with high TB burden Adults not previously vaccinated in close contact with persons with known MDR Mtb
30 CDC Guidelines Not recommended for routine use in the United States Three exceptions: Children exposed to persons who have TB and cannot be treated Children exposed to person with INH and RIF resistant-tb HCW with prolonged exposure to persons with MDR-TB CDC, 2011
31 BCG and TST If a TST is 10mm in a person previously vaccinated with BCG, SUSPECT TB INFECTION CDC Guidelines: TST 10mm considered positive if: The vaccinated person is a contact of another person who has infectious TB, particularly if the infectious person has transmitted M. tuberculosis to others The vaccinated person was born or has resided in a country in which the prevalence of TB is high The vaccinated person is exposed continually to populations in which the prevalence of TB is high (e.g., some health care workers, employees and volunteers at homeless shelters, and workers at drug-treatment centers) Klinik BTP
32 BCG and Non-muscle Invasive Bladder Cancer 1976: Morales et al. reported resolution of superficial bladder tumor in 9 patients who received intradermal and intravesical BCG (Dose: 120mg once weekly for 6 weeks) 1982: Brosman et al. reported similar efficacy without intradermal dosing in patients with recurrent superficial bladder cancer Dose: 120mg weekly x 6 weeks, 120mg q 2 weeks x 12 weeks, 120mg monthly x 2 years 0/26 recurrences in BCG group; 9/23 recurrences in thio-tepa group at 24 wks J Urol 1976;116:180-3 J Urol 1982;128:27-30
33 BCG for Superficial Bladder Cancer Metanalysis of 25 RCT, 4767 patients OR for Recurrence: 0.61 (0.46,0.80) OR for Recurrence (TUR + BCG v. TUR alone): 0.35 (0.20,0.59) BCG superior to all other intravesical agents Consensus Recommendations 6 weeks of weekly induction starting 2-6 weeks post TURBT 3-weekly doses q 6 months thru 36 months 81mg Connaught strain (Theracys ) OR 50mg of Tice strain (OncoTICE ) retained for 2 hours Adjuvant for high-grade tumors only Sanofi Pasteur Urology 67 (6), 2006 Nat Rev Urol Apr;12(4):225-35
34 How does it work? BCG antigenicity Overwhelming inflammatory response CD4 T-cells, macrophages inflammatory cytokines IFN-gamma Direct suppression of tumor cells by BCG?
35
36 Complications of Intravesical BCG Common Cystitis (67%) Fever (25%) Hematuria (23%) Flu-Like Illness (15%) Severe (<1%) Prostatitis Pneumonitis Sepsis Lumbar Osteomyelitis AAA (18 cases reported) Clin Infect Dis. 2000;31 Suppl 3:S86.
37 Other medical uses of BCG Autologous tumor cells + BCG for stage II colon cancer Intralesional BCG for melanoma
38 Conclusion BCG vaccine confers some protection against pulmonary TB, but when and where to use it remains unclear If BCG vaccinated and positive TST, likely LTBI Vaccination policies vary widely globally Role of BCG on decreasing burden of tuberculosis worldwide is limited Better vaccines are needed
39 Questions or Comments?
Summary of Key Points WHO Position Paper on BCG Vaccine, February 2018
Summary of Key Points WHO Position Paper on BCG Vaccine, February 2018 1 Introduction This position paper replaces the 2004 WHO position paper on Bacille Calmette-Guérin (BCG) vaccine and the 2007 WHO
More informationUpdate on TB Vaccines. Mark Hatherill South African TB Vaccine Initiative (SATVI) University of Cape Town
Update on TB Vaccines Mark Hatherill South African TB Vaccine Initiative (SATVI) University of Cape Town 1 Robert Koch s Therapeutic TB vaccine 1890: Purified Tuberculin Protein 1891: First negative reports
More informationTB PREVENTION: TREATMENT OF LATENT TB INFECTION AND BCG VACCINATION
TB PREVENTION: TREATMENT OF LATENT TB INFECTION AND BCG VACCINATION Michelle Haas, M.D. Denver Metro Tuberculosis Program Denver Public Health DISCLOSURES No relevant financial relationships OBJECTIVES
More informationGlobal progress in vaccine development
Global progress in vaccine development Helen McShane The Jenner Institute University of Oxford helen.mcshane@ndm.ox.ac.uk Vaccination The most cost-effective health intervention Smallpox Poliomyelitis
More informationESCMID Online Lecture Library. by author
Tuberculosis prevention in immunodepressed patients M. Carmen Fariñas Álvarez Infectious Diseases.H.U.Marqués de Valdecilla University of Cantabria, Spain DISCLOSURES I have no potential conflicts with
More informationVII Jornadas Catalanas de Salud Internacional
VII Jornadas Catalanas de Salud Internacional BCG vaccine Why BCG Facts and history of BCG Protective efficacy Duration of protection Immunisation coverage Recommendations Revaccination Adverse effects
More informationCHAPTER 3: DEFINITION OF TERMS
CHAPTER 3: DEFINITION OF TERMS NOTE: TB bacteria is used in place of Mycobacterium tuberculosis and Mycobacterium tuberculosis complex in most of the definitions presented here. 3.1 Acid-fast bacteria
More information2016 OPAM Mid-Year Educational Conference, Sponsored by AOCOPM Sunday, March 13, 2016
Learning Objectives Tuberculosis Case Discussions: Evaluation for Tuberculosis Infection Melissa C. Overman, DO, MPH, CHES, FAOCOPM Describe appropriate technique for TST placement, reading and interpretation
More informationTUBERCULOSIS IN HEALTHCARE SETTINGS Diana M. Nilsen, MD, FCCP Director of Medical Affairs, Bureau of Tuberculosis Control New York City Department of
TUBERCULOSIS IN HEALTHCARE SETTINGS Diana M. Nilsen, MD, FCCP Director of Medical Affairs, Bureau of Tuberculosis Control New York City Department of Health and Mental Hygiene TODAY S PRESENTATION Epidemiology
More informationTB, BCG and other things. Chris Conlon Infectious Diseases Oxford
TB, BCG and other things Chris Conlon Infectious Diseases Oxford Epidemiology Latent TB IGRA BCG >50/100000
More informationTuberculosis Tools: A Clinical Update
Tuberculosis Tools: A Clinical Update CAPA Conference 2014 JoAnn Deasy, PA-C. MPH, DFAAPA jadeasy@sbcglobal.net Adjunct Faculty Touro PA Program Learning Objectives Outline the pathogenesis of active pulmonary
More informationLatent Tuberculosis Infections Controversies in Diagnosis and Management Update 2016
Latent Tuberculosis Infections Controversies in Diagnosis and Management Update 2016 Randy Culpepper, MD, MPH Deputy Heath Officer/Medical Director Frederick County Health Department March 16, 2016 2 No
More informationPeggy Leslie-Smith, RN
Peggy Leslie-Smith, RN EMPLOYEE HEALTH DIRECTOR - AVERA TRAINING CONTENT 1. South Dakota Regulations 2. Iowa Regulations 3. Minnesota Regulations 4. Interferon Gamma Release Assay (IGRA)Testing 1 SOUTH
More informationTB In Detroit 2011* Early TB: Smudge Sign. Who is at risk for exposure to or infection with TB? Who is at risk for TB after exposure or infection?
Those oral antibiotics are just not working! Inpatient Standards of Care & Discharge Planning S/He s in the Hospital: Now What Do I Do? Dana G. Kissner, MD TB Intensive Workshop, Lansing, MI 2012 Objectives:
More informationTuberculosis (TB) Fundamentals for School Nurses
Tuberculosis (TB) Fundamentals for School Nurses June 9, 2015 Kristin Gall, RN, MSN/Pat Infield, RN-TB Program Manager Marsha Carlson, RN, BSN Two Rivers Public Health Department Nebraska Department of
More information11/1/2017. Disclosures. Update In Tuberculosis, Indiana Outline/Objectives. Pathogenesis of M.tb Global/U.S. TB Burden, 2016
Disclosures Update In Tuberculosis, Indiana 2017 Bradley Allen, MD, PhD, FACP, FIDSA Indiana University School of Medicine Division of Infectious Diseases Roudebush VAMC Indianapolis Medical Consultant,
More informationFundamentals of Tuberculosis (TB)
TB in the United States Fundamentals of Tuberculosis (TB) From 1953 to 1984, reported cases decreased by approximately 5.6% each year From 1985 to 1992, reported cases increased by 20% 25,313 cases reported
More informationTB: Management in an era of multiple drug resistance. Bob Belknap M.D. Denver Public Health November 2012
TB: Management in an era of multiple drug resistance Bob Belknap M.D. Denver Public Health November 2012 Objectives: 1. Explain the steps for diagnosing latent and active TB role of interferon-gamma release
More informationBCG. History Strains Recommendations Efficacy Safety Heterologous effects Worldwide shortage Pragmatics
BCG vaccine update Jim Buttery Monash Children s Hospital Murdoch Childrens Research Institute The Ritchie Centre Department of Paediatrics, Monash University BCG History Strains Recommendations Efficacy
More information7. BCG Vaccination HSE/HPSC. Guidelines on the Prevention and Control of Tuberculosis in Ireland IUATLD criteria
7. BCG Vaccination The Bacillus Calmette-Guerin (BCG) vaccine was derived by in-vitro attenuation of the bovine tubercle bacillus between the years 1908 and 1918 in France. WHO encouraged widespread use
More informationContents 1. HISTORY 2. CHARACTERSTICS 3. VACCINATION
SEMINAR ON BCG Contents 1. HISTORY 2. CHARACTERSTICS 3. VACCINATION Introduction Tuberculosis remain world wide public health problem and especially major public health problem in India. Tuberculosis Control
More informationPreventing Tuberculosis (TB) Transmission in Ambulatory Surgery Centers. Heidi Behm, RN, MPH TB Controller HIV/STD/TB Program
Preventing Tuberculosis (TB) Transmission in Ambulatory Surgery Centers Heidi Behm, RN, MPH TB Controller HIV/STD/TB Program Topics of Discussion TB Overview Epidemiology of TB in Oregon Annual Facility
More informationMedical Bacteriology- Lecture 10. Mycobacterium. Actinomycetes. Nocardia
Medical Bacteriology- Lecture 10 Mycobacterium Actinomycetes Nocardia 1 Mycobacterium Characteristics - Large, very weakly gram positive rods - Obligate aerobes, related to Actinomycetes - Catalase positive
More informationSelf-Study Modules on Tuberculosis
Self-Study Modules on Tuberculosis Targe te d Te s ting and the Diagnosis of Latent Tuberculosis Infection and Tuberculosis Disease U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Disease Control
More informationPREVENTION OF TUBERCULOSIS. Dr Amitesh Aggarwal
PREVENTION OF TUBERCULOSIS Dr Amitesh Aggarwal 25 to 50 % of persons exposed to intimate contact with active PTB - latent infection with TB. Exposure to index case for 12 hours - high risk of infection.
More informationTB in Corrections Phoenix, Arizona
TB in Corrections Phoenix, Arizona March 24, 2011 Treatment of Latent TB Infection Renuka Khurana MD, MPH March 24, 2011 Renuka Khurana, MD, MPH has the following disclosures to make: No conflict of interests
More informationOsteomyelitis Caused by Bacille Calmette-Gu (BCG) Vaccination: 2 Cases
Osteomyelitis Caused by Bacille Calmette-Gu Guérin (BCG) Vaccination: 2 Cases Yoo, WonJoon Seoul National University Children s Hospital Seoul, Korea CASE 1 M / 11mos Pain & LOM, Knee, Rt. Swelling at
More informationTable 9. Policy for Tuberculosis Surveillance and Screening
Policy for Tuberculosis Surveillance and Screening Purpose: to identify active cases of tuberculosis or latent TB among residents and staff of the nursing home in order to prevent transmission in this
More informationContracts Carla Chee, MHS May 8, 2012
Moving Past the Basics of Tuberculosis Phoenix, Arizona May 8-10, 2012 Contracts Carla Chee, MHS May 8, 2012 Carla Chee, MHS has the following disclosures to make: No conflict of interests No relevant
More informationTUBERCULOSIS. Presented By: Public Health Madison & Dane County
TUBERCULOSIS Presented By: Public Health Madison & Dane County What is Tuberculosis? Tuberculosis, or TB, is a disease caused by a bacteria called Mycobacterium tuberculosis. The bacteria can attack any
More information10/3/2017. Updates in Tuberculosis. Global Tuberculosis, WHO 2015 report. Objectives. Disclosures. I have nothing to disclose
Disclosures Updates in Tuberculosis I have nothing to disclose Chris Keh, MD Assistant Clinical Professor, Division of Infectious Diseases, UCSF TB Controller, TB Prevention and Control Program, Population
More informationResearch in Tuberculosis: Translation into Practice
Case History Research in Tuberculosis: Translation into Practice This is a 6-year6 year-old Bosnian male, who presented to ER with one-week history of fever and occasional vomiting. No cough, difficulty
More informationPerspective in novel TB vaccine development Mohamed Ridha BARBOUCHE M.D., Ph.D. Department of Immunology Institut Pasteur de Tunis
Perspective in novel TB vaccine development Mohamed Ridha BARBOUCHE M.D., Ph.D. Department of Immunology Institut Pasteur de Tunis Existing TB Vaccine is not effective for global TB epidemic control BCG
More informationCommunity pharmacy-based tuberculosis skin testing
Community pharmacy-based tuberculosis skin testing Shanna K. O Connor, PharmD ISU KDHS Spring CE Seminar 2018 In support of improving patient care, Idaho State University Kasiska Division of Health Sciences
More informationCommunicable Disease Control Manual Chapter 4: Tuberculosis
Provincial TB Services 655 West 12th Avenue Vancouver, BC V5Z 4R4 www.bccdc.ca Communicable Disease Control Manual Definitions Page 1 2.0 DEFINITIONS Many of the definitions that follow are taken from
More informationTB trends and TB genotyping
Management of a TB Contact Investigation for Public Health Workers Albuquerque, NM October 1, 214 TB trends and TB genotyping Marcos Burgos MD October 1, 214 Marcos Burgos, MD has the following disclosures
More informationMycobacterial Infections: What the Primary Provider Should Know about Tuberculosis
Mycobacterial Infections: What the Primary Provider Should Know about Tuberculosis Henry F. Chambers, M.D Professor of Medicine, UCSF Topics for Discussion Epidemiology Diagnosis of active TB Screening
More informationTB Transmission, Pathogenesis & Infection Control
TB Transmission, Pathogenesis & Infection Control Bradley Allen, MD, PhD, FACP, FIDSA. 2014 MFMER slide-1 Disclosures Medical Consultant, TB Control Program Indiana State Department of Health Past clinical
More informationReviewing Immunotherapy for Bladder Carcinoma In Situ
Reviewing Immunotherapy for Bladder Carcinoma In Situ Samir Bidnur Dept of Urologic Sciences, Grand Rounds March 1 st, 2017 Checkpoint Inhibition and Bladder Cancer, an evolving story with immunotherapy
More informationTUBERCULOSIS. Pathogenesis and Transmission
TUBERCULOSIS Pathogenesis and Transmission TUBERCULOSIS Pathogenesis and Transmission Infection to Disease Diagnostic & Isolation Updates Treatment Updates Pathogenesis Droplet nuclei of 5µm or less are
More informationTuberculosis Elimination: The Role of the Infection Preventionist
Tuberculosis Elimination: The Role of the Infection Preventionist Preface: What Happens when Health Care Professionals are not familiar with TB? A 15 year old student was diagnosed with highly infectious
More informationMonitoring tuberculosis progression using MRI and stereology
Monitoring tuberculosis progression using MRI and stereology TB the problem Estimated number of new cases in 2007 2 million deaths; 9 million new cases p.a. TB kills someone every 15 secs, 9,153 cases
More informationDiagnosis and Medical Management of Latent TB Infection
Diagnosis and Medical Management of Latent TB Infection Marsha Majors, RN September 7, 2017 TB Contact Investigation 101 September 6 7, 2017 Little Rock, AR EXCELLENCE EXPERTISE INNOVATION Marsha Majors,
More informationPediatric TB Lisa Armitige, MD, PhD September 28, 2011
TB Nurse Case Management Davenport, Iowa September 27 28, 2011 Pediatric TB Lisa Armitige, MD, PhD September 28, 2011 Lisa Armitige, MD, PhD has the following disclosures to make: No conflict of interest.
More informationApplication of New Diagnostics and Preventative Treatment in Low and High Burden Settings
Application of New Diagnostics and Preventative Treatment in Low and High Burden Settings Edward Nardell, MD Brigham & Women s Hospital Harvard Medical School Partners In Health Disclosures opps! Served
More informationLATENT TUBERCULOSIS. Robert F. Tyree, MD
LATENT TUBERCULOSIS Robert F. Tyree, MD 1 YK TB OFFICERS Ron Bowerman Elizabeth Roll Mien Chyi (Pediatrics) Cindi Mondesir (Pediatrics) The new guys: Philip Johnson Robert Tyree 2009 CDC TB CASE DEFINITION
More informationDetection and Treatment of Tuberculosis in Correctional Facilities: Opportunities and Challenges
Detection and Treatment of Tuberculosis in Correctional Facilities: Opportunities and Challenges David Karol, MD, MA Bureau of Prisons, FMC Butner Duke University Medical Center June 26, 2013 No Disclosures
More informationTargeted Testing and the Diagnosis of. Latent Tuberculosis. Infection and Tuberculosis Disease
Self-Study Study Modules on Tuberculosis Targeted Testing and the Diagnosis of Latent Tuberculosis Infection and Tuberculosis Disease 1 Module 3: Objectives At completion of this module, learners will
More informationTransmission of DS-TB and MDR-TB. C. Robert Horsburgh, Jr. Boston University School of Public Health
Transmission of DS-TB and MDR-TB C. Robert Horsburgh, Jr. Boston University School of Public Health Outline Epidemiologic factors in transmission Ability of the transmitter to transmit Susceptibility of
More informationManagement of High Grade, T1 Bladder Cancer Douglas S. Scherr, M.D.
Management of High Grade, T1 Bladder Cancer Douglas S. Scherr, M.D. Assistant Professor of Urology Clinical Director, Urologic Oncology Weill Medical College-Cornell University Estimated new cancer cases.
More informationProgrammatic management of LTBI : a two pronged approach for ending the TB epidemic. Haileyesus Getahun Global TB Programme WHO/HQ
Programmatic management of LTBI : a two pronged approach for ending the TB epidemic Haileyesus Getahun Global TB Programme WHO/HQ What is latent TB infection? A state of persistent immune response to stimulation
More informationMedical Bacteriology- lecture 13. Mycobacterium Actinomycetes
Medical Bacteriology- lecture 13 Mycobacterium Actinomycetes Mycobacterium tuberculosis Large, very weakly gram positive rods, Obligate aerobes, related to Actinomycetes, non spore forming, non motile
More informationDiagnosis & Medical Case Management of TB Disease. Lisa Armitige, MD, PhD October 22, 2015
Diagnosis & Medical Case Management of TB Disease Lisa Armitige, MD, PhD October 22, 2015 Comprehensive Care of Patients with Tuberculosis and Their Contacts October 19 22, 2015 Wichita, KS EXCELLENCE
More informationEvaluation and Treatment of TB Contacts Tyler, Texas April 11, 2014
Evaluation and Treatment of TB Contacts Tyler, Texas April 11, 2014 Interferon Gamma Release Assays: Understanding the Test David Griffith, BA, MD April 11, 2014 David Griffith, BA, MD has the following
More informationTB the basics. (Dr) Margaret (DHA) and John (INZ)
TB the basics (Dr) Margaret (DHA) and John (INZ) Question 1 The scientist who discovered M. tuberculosis was: A: Louis Pasteur B: Robert Koch C: Jean-Antoine Villemin D: Calmette and Guerin Question 2
More informationMODULE ONE" TB Basic Science" Treatment Action Group TB/HIV Advocacy Toolkit
MODULE ONE" TB Basic Science" Treatment Action Group TB/HIV Advocacy Toolkit Topics to be covered What is Tuberculosis? TB bacteria and what is unique about it. How is TB different from HIV? How is TB
More informationTB Intensive San Antonio, Texas November 11 14, 2014
TB Intensive San Antonio, Texas November 11 14, 2014 Interferon Gamma Release Assays Lisa Armitige, MD, PhD November 12, 2014 Lisa Armitige, MD, PhD has the following disclosures to make: No conflict of
More informationTuberculosis Intensive
Tuberculosis Intensive San Antonio, Texas April 3 6, 2012 Childhood Tuberculosis Kim Smith, MD, MPH April 6, 2012 Kim Smith, MD, MPH has the following disclosures to make: No conflict of interests No relevant
More informationTuberculosis Populations at Risk
Tuberculosis Populations at Risk One-third of the world is infected with TB, an average of one new infection per second Two million people died from tuberculosis in 2010, 1 every 20 seconds TB is the leading
More informationLatent TB Infection (LTBI) Strategies for Detection and Management
Latent TB Infection (LTBI) Strategies for Detection and Management Patrick T. Dowling MD,MPH Professor and Chair Dept of Family Medicine David Geffen School of Medicine at UCLA Pri-Med March 29 2014 Pdowling@mednet.ucla.edu
More informationManagement of Pediatric Tuberculosis in New Jersey
Management of Pediatric Tuberculosis in New Jersey Helen Aguila, MD NJMS Global TB Institute December 15, 2011 This presentation is in part adapted from Pediatric Tuberculosis by Ann Loeffler, MD : Francis
More informationProtection by BCG Vaccine Against Tuberculosis: A Systematic Review of Randomized Controlled Trials
MAJOR ARTICLE Protection by BCG Vaccine Against Tuberculosis: A Systematic Review of Randomized Controlled Trials Punam Mangtani, 1 Ibrahim Abubakar, 2,3 Cono Ariti, 1 Rebecca Beynon, 4 Laura Pimpin, 2,5
More informationTuberculosis Pathogenesis
Tuberculosis Pathogenesis Renuka Khurana, MD, MPH May 12, 2015 TB for Community Providers May 12, 2015 Phoenix, Arizona EXCELLENCE EXPERTISE INNOVATION Renuka Khurana, MD, MPH has the following disclosures
More informationCOFM Immunization Policy 2016
COFM Immunization Policy 2016 Council of Ontario Faculties of Medicine June 2016 COUNCIL OF ONTARIO FACULTIES OF MEDICINE An affiliate of the Council of Ontario Universities COFM Immunization Policy 2016
More informationTB Intensive Houston, Texas. Childhood Tuberculosis Kim Connelly Smith. November 12, 2009
TB Intensive Houston, Texas November 10-12, 12 2009 Childhood Tuberculosis Kim Connelly Smith MD, MPH November 12, 2009 Childhood Tuberculosis Kim Connelly Smith MD, MPH November 12, 2009 1 OUTLINE Stages
More informationCharacteristics of Mycobacterium
Mycobacterium Characteristics of Mycobacterium Very thin, rod shape. Culture: Aerobic, need high levels of oxygen to grow. Very slow in grow compared to other bacteria (colonies may be visible in up to
More informationLecture 17: Vaccines (Therapeutic and Prophylactic Types)
Lecture 17: Vaccines (Therapeutic and Prophylactic Types) Therapeutic vaccines Bacillus Calmette Guerin (BCG; TheraCys) Very old agent initially developed as vaccine for MTB. Uses: Superficial bladder
More informationCHILDHOOD TUBERCULOSIS: NEW WRINKLES IN AN OLD DISEASE [FOR THE NON-TB EXPERT]
CHILDHOOD TUBERCULOSIS: NEW WRINKLES IN AN OLD DISEASE [FOR THE NON-TB EXPERT] QUESTION: : Which children in the United States should get a tuberculin skin test? Do questionnaires really work? Jeffrey
More informationTuberculosis Infection in the US Military
Tuberculosis Infection in the US Military Edward Munch. The Sick Child. (1885) Anjali Kunz, MAJ (P), MC Pediatric Infectious Disease, Chief, JBLM Courtesy of : Paul B. Keiser, Feb 2014 Walter Reed Army
More informationTuberculosis. WRAIR- GEIS 'Operational Clinical Infectious Disease' Course UNCLASSIFIED
Tuberculosis WRAIR- GEIS 'Operational Clinical Infectious Disease' Course UNCLASSIFIED Acknowledgments COL Paul Keiser LTC James E. Moon LTC Jaime Mancuso LTC Anjali Kunz MAJ Kristopher Paolino MAJ Leyi
More informationNew Tuberculosis Guidelines. Jason Stout, MD, MHS
New Tuberculosis Guidelines Jason Stout, MD, MHS Two New Sets of Guidelines Treatment of Drug-Susceptible Tuberculosis Clinical Infectious Diseases 2016; 63(7): e147-e195 Diagnosis of Tuberculosis in Adults
More informationSelf-Study Modules on Tuberculosis
Self-Study Modules on Tuberculosis Transmission and Pathogenesis of Tube rc ulos is U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Disease Control and Prevention National Center for HIV/AIDS,
More informationAdvanced Management of Patients with Tuberculosis Little Rock, Arkansas August 13 14, 2014
Advanced Management of Patients with Tuberculosis Little Rock, Arkansas August 13 14, 2014 Tuberculosis Pathogenesis and Treatment of Latent TB Infection Lisa Armitige, MD, PhD August 13, 2014 Lisa Armitige,
More informationTB Intensive Houston, Texas October 15-17, 2013
TB Intensive Houston, Texas October 15-17, 2013 Interferon Gamma Release Assays (IGRA s) Lisa Armitige, MD, PhD October 16, 2013 Lisa Armitige, MD, PhD has the following disclosures to make: No conflict
More informationMaking the Diagnosis of Tuberculosis
Making the Diagnosis of Tuberculosis Alfred Lardizabal, MD NJMS Global Tuberculosis Institute Testing for TB Infection Targeted Testing: Key Points Test only if plan for ensuring treatment De-emphasizes
More informationLatent Tuberculosis Best Practices
Latent Tuberculosis Best Practices Last Updated September 7, 2016 LTBI Demographics in the US o 13million people in the US with LTBI (estimate) o In 2014, approximately 66% of TB cases in the United States
More informationTuberculosis 6/7/2018. Objectives. What is Tuberculosis?
Tuberculosis Understanding, Investigating, Eliminating Jeff Maupin, RN Tuberculosis Control Nurse Sedgwick County Division of Health Objectives At the conclusion of this presentation, you will be able
More informationTB vaccine progress. Hassan Mahomed. Institute of Infectious Disease and Molecular Medicine, School of Child and Adolescent Health,
TB vaccine progress Hassan Mahomed South African TB Vaccine Initiative (SATVI), Institute of Infectious Disease and Molecular Medicine, School of Child and Adolescent Health, University of Cape Town, South
More informationDescriptive Epidemiology Project: Tuberculosis in the. United States. MPH 510: Applied Epidemiology. Summer A 2014
Descriptive Epidemiology Project: Tuberculosis in the United States MPH 510: Applied Epidemiology Summer A 2014 June 1, 2014 1 The white plague affected thousands upon thousands of people in the 18 th
More informationUnderstanding and Managing Latent TB Infection Arnold, Missouri October 5, 2010
Understanding and Managing Latent TB Infection Arnold, Missouri October 5, 2010 What is Latent TB Infection (LTBI)? Traci Hadley, RN October 5, 2010 LTBI or TB Disease? Presented by : Traci Hadley, RN
More informationTB Epidemiology. Richard E. Chaisson, MD Johns Hopkins University Center for Tuberculosis Research
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike License. Your use of this material constitutes acceptance of that license and the conditions of use of materials on this
More informationApproaches to LTBI Diagnosis
Approaches to LTBI Diagnosis Focus on LTBI October 8 th, 2018 Michelle Haas, M.D. Associate Director Denver Metro Tuberculosis Program Denver Public Health DISCLOSURES I have no disclosures or conflicts
More informationTuberculosis Intensive
Tuberculosis Intensive San Antonio, Texas April 3 6, 2012 Tuberculosis Pathogenesis Lynn Horvath, MD April 3, 2012 Lynn Horvath, MD has the following disclosures to make: No conflict of interests No relevant
More informationPrevalence of tuberculosis (TB) infection and disease among adolescents western Kenya: preparation for future TB vaccine trials
Prevalence of tuberculosis (TB) infection and disease among adolescents western Kenya: preparation for future TB vaccine trials Videlis Nduba 1,2, Peter Onyango 1, Anja Van t Hoog 1,3, Anthony Hawkridge
More informationDownloaded from:
Mangtani, P; Abubakar, I; Ariti, C; Beynon, R; Pimpin, L; Fine, PE; Rodrigues, LC; Smith, PG; Lipman, M; Whiting, PF; Sterne, JA (2013) Protection by BCG against tuberculosis: a systematic review of randomised
More information2016 Annual Tuberculosis Report For Fresno County
206 Annual Tuberculosis Report For Fresno County Cases Rate per 00,000 people 206 Tuberculosis Annual Report Fresno County Department of Public Health (FCDPH) Tuberculosis Control Program Tuberculosis
More informationAnnual Tuberculosis Report Oregon 2007
Annual Tuberculosis Report Oregon 7 Oregon Department of Human Services Public Health Division TB Program April 8 Page 2 Table of Contents Charts Chart 1 TB Incidence in the US and Oregon, 1985-7.. page
More informationAt the end of this session, participants will be able to:
Advanced Concepts in Pediatric Tuberculosis: Infection Control, Source Case and Contact Investigation Ana M. Alvarez, M.D. Associate Professor Division of Pediatric Infectious Diseases and Immunology University
More informationTesting for Tuberculosis Infection and Disease: The Expanding Role of Blood-based Assays
Complimentary CME Testing for Tuberculosis Infection and Disease: The Expanding Role of Blood-based Assays POWERED BY Program Description Screening and testing guidelines are an important component in
More informationBarbara J Seaworth MD Medical Director, Heartland National TB Center Professor, Internal Medicine and Infectious Disease UT Health Northeast
Practical Aspects for Using the Interferon Gamma Release Assay (IGRA) Test Live Webinar July 14, 2017 Barbara J Seaworth MD Medical Director, Heartland National TB Center Professor, Internal Medicine and
More informationTB Nurse Case Management San Antonio, Texas July 18 20, 2012
TB Nurse Case Management San Antonio, Texas July 18 20, 2012 Pediatric TB Kim Smith, MD, MPH July 19, 2012 Kim Smith, MD, MPH has the following disclosures to make: No conflict of interests No relevant
More informationTB Intensive San Antonio, Texas December 1-3, 2010
TB Intensive San Antonio, Texas December 1-3, 2010 TB Pathogenesis and Transmission Lynn Horvath, MD; TCID December 1, 2010 Tuberculosis Pathogenesis Lynn L. Horvath, MD, FACP, FIDSA Associate Professor
More informationTuberculosis: Where Are We Now?
Tuberculosis: Where Are We Now? Amee Patrawalla MD MPH Rutgers - NJ Medical School Global TB Institute Rutgers, The State University of New Jersey Learning Objectives Understand the current epidemiologic
More informationTargeted Tuberculin Testing and Treatment of Latent Tuberculosis Infection (LTBI) Lloyd Friedman, M.D. Milford Hospital Yale University
Targeted Tuberculin Testing and Treatment of Latent Tuberculosis Infection (LTBI) Lloyd Friedman, M.D. Milford Hospital Yale University Tuberculosis Estimates USA World Infection 15,000,000 2,000,000,000
More informationhas the following disclosures to make:
CLINICAL DIAGNOSIS AND MANAGEMENT OF TB DISEASE Annie Kizilbash MD, MPH September 22, 2015 TB Nurse Case Management September 22 24, 2015 San Antonio. TX EXCELLENCE EXPERTISE INNOVATION Annie Kizilbash
More informationPrimary Care and TB Control Dr Helen Booth Consultant Thoracic Physician, UCLH Clinical Lead, Integrated TB NCL-Service
Primary Care and TB Control Dr Helen Booth Consultant Thoracic Physician, UCLH Clinical Lead, Integrated TB NCL-Service North Central London TB Service TBService@nhs.net After Action Review Could we have
More informationTB is Global. Latent TB Infection (LTBI) Sharing the Care: Working Together. September 24, 2014
Sharing the Care: Working Together to Meet the Challenge of TB Presented by: Barbara Cole, RN, PHN, MSN Director, Disease Control County of Riverside Department of Public Health Curry International TB
More informationYakima Health District BULLETIN
Yakima Health District BULLETIN Summary Volume 13, Issue 1 February, 2014 Tuberculosis in Yakima County The rate of active tuberculosis (TB) in Yakima County has declined by about two-thirds over the past
More informationDIAGNOSIS AND MEDICAL MANAGEMENT OF TB DISEASE
DIAGNOSIS AND MEDICAL MANAGEMENT OF TB DISEASE Annie Kizilbash MD, MPH Assistant Professor University of Texas Health Science Center Staff Physician, Texas Center for Infectious Diseases TB Nurse Case
More information